Skip to main content

Table 5 Multinomial logistic regression analysis by treatment category

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

 

Correct Treatment

Physician counsels patient on all treatment options

No Prostate Cancer Treatment

 

Odds ratio

95% Confidence Interval

P-value

Odds ratio

95% Confidence Interval

P-value

Odds ratio

95% Confidence Interval

P-value

Intervention

0.94

(0.47,1.82)

0.860

0.57

(0.338,1.00)

0.050

0.99

(0.56,1.72)

0.960

Interaction Round with Study Arm

2.84

(1.39,5.82)

0.004

2.72

(1.47, 5.05)

0.001

0.98

(0.50,1.89)

0.946

Onsite robotics capacity

0.87

(0.51,1.49)

0.608

0.92

(0.59,1.44)

0.716

0.78

(0.49,1.26)

0.318

More than 20 prostate cancer patients per week

0.64

(0.35,1.15)

0.138

0.43

(0.26,0.70)

0.001

0.56

(0.33,0.95)

0.031

More than 100 urology patients per week

1.14

(0.64,2.03)

0.652

1.10

(0.69,1.78)

0.682

1.36

(0.81,2.26)

0.243

Greater than 50% public payors

0.99

(0.97,1.01)

0.400

1.00

(0.98,1.02)

0.889

1.00

(0.98,1.02)

0.768

Age over 40

1.02

(0.99,1.05)

0.217

1.01

(0.98,1.04)

0.435

1.05

(1.02,1.08)

0.000

Physician-owned practice

1.21

(0.49,2.95)

0.678

0.82

(0.41,1.64)

0.572

1.20

(0.55,2.64)

0.648

Constant

0.56

(0.05,6.03)

0.636

4.27

(0.63,28.78)

0.136

0.38

(0.05,2.92)

0.354

  1. Incorrect treatment is the baseline treatment mode. Model also controls for CPV case type